Background A spot mutation (V600E) in the oncogene is a prognostic biomarker and could predict for non response to anti-EGFR antibody therapy in digestive tract carcinomas. cell cytoplasm in 74 Rabbit Polyclonal to AN30A. of 75 digestive tract carcinomas. A mutation-specific antibody determined diffuse cytoplasmic staining of mutant BRAFV600E proteins in 49 of 74 malignancies.… Continue reading Background A spot mutation (V600E) in the oncogene is a prognostic